51
|
Yoo C, Oh DY, Choi H, Kudo M, Ueno M, Kondo S, Chen LT, Osada M, Helwig C, Dussault I, Ikeda M. M7824 (MSB0011359C), a bifunctional fusion protein targeting transforming growth factor β (TGF-β) and PD-L1, in Asian patients with pretreated biliary tract cancer (BTC): Efficacy by BTC subtype. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy432.005] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
52
|
Heo J, Cheng AL, Raoul JL, Peck-Radosavljevic M, Kudo M, Nakajima K, Bayh I, Lin SM, Lee H. Practice patterns, radiologic tumor response, and deterioration of liver function after transarterial chemoembolization (TACE): Final analysis of OPTIMIS in Korea and other regions. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy432.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
53
|
Kang YK, Kudo M, Lim HY, Hsu CH, Vogel A, Brandi G, Cheng R, Carton I, Abada P, Hsu Y, Zhu A, Yen CJ. Efficacy and safety of ramucirumab (RAM) in Asian and non-Asian patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP): Subgroup analysis from two randomized studies. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy432.001] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
54
|
Qin S, Finn R, Kudo M, Meyer T, Vogel A, Ducreux M, Macarulla T, Tomasello G, Boisserie F, Hou J, Li C, Song J, Zhu A. Global phase III study of tislelizumab versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma (HCC): A trial-in-progress. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy282.159] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
55
|
Raoul JL, Decaens T, Burak K, Koskinas J, Villadsen G, Heurgue-Berlot A, Bayh I, Cheng AL, Kudo M, Lee H, Nakajima K, Peck-Radosavljevic M. Practice patterns and deterioration of liver function after transarterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): Final analysis of OPTIMIS in Europe and Canada. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy282.093] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
56
|
Finn R, Kudo M, Cheng AL, Wyrwicz L, Ngan R, Blanc J, Baron A, Vogel A, Ikeda M, Piscaglia F, Han KH, Qin S, Minoshima Y, Kanekiyo M, Ren M, Dairiki R, Tamai T, Dutcus C, Funahashi Y, Evans T. Final analysis of serum biomarkers in patients (pts) from the phase III study of lenvatinib (LEN) vs sorafenib (SOR) in unresectable hepatocellular carcinoma (uHCC) [REFLECT]. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy269.057] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
57
|
Yoo C, Oh DY, Choi H, Kudo M, Ueno M, Kondo S, Chen LT, Osada M, Helwig C, Dussault I, Ikeda M. M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-β, in Asian patients with pretreated biliary tract cancer: Preliminary results from a phase I trial. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy282.140] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
58
|
Zhu A, Finn R, Galle P, Llovet J, Blanc J, Okusaka T, Chau I, Cella D, Girvan A, Gable J, Bowman L, Hsu Y, Abada P, Kudo M. Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first-line sorafenib: Patient reported outcome results across two phase III studies (REACH-2 and REACH). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy282.006] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
59
|
Cheng AL, Yen CJ, Okusaka T, Ikeda M, Hsu CH, Wu SY, Morizane C, Hashimoto Y, Ueshima K, Ohtomo T, Tanaka T, Kudo M. A phase I, open-label, multi-center, dose-escalation study of codrituzumab, an anti-glypican-3 monoclonal antibody, in combination with atezolizumab in patients with locally advanced or metastatic hepatocellular carcinoma. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy282.080] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
60
|
Zhu A, Finn R, Galle P, Llovet J, Blanc JF, Okusaka T, Chau I, Abada P, Hsu Y, Kudo M. Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first-line sorafenib: Pooled efficacy and safety across two global randomized Phase 3 studies (REACH-2 and REACH). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy208] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
61
|
Chan S, Finn R, Zhu A, Knox J, Cheng AL, Siegel A, Bautista O, Kudo M. Phase 3, randomized KEYNOTE-240 study of pembrolizumab (Pembro) versus best supportive care (BSC) for second-line advanced hepatocellular carcinoma (HCC). Ann Oncol 2017. [DOI: 10.1093/annonc/mdx666.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
62
|
Choo S, Yau T, Hsu C, Kang YK, Hou MM, Yeo W, Numata K, Chopra A, Baakili A, Dela Cruz C, Zhao H, Kudo M. Efficacy and safety of nivolumab in asian patients with advanced hepatocellular carcinoma (HCC): Subanalysis of the CheckMate 040 Study. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx660.002] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
63
|
Nishihira J, Nishimura M, Sugawara M, Kudo M. Double-blind, parallel group, placebo-controlled study of Kjellmaniella crassifolia Miyabe (Gagome) in human: The potential of Gagome to activate the immune system. FUNCTIONAL FOODS IN HEALTH AND DISEASE 2017. [DOI: 10.31989/ffhd.v7i10.390] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Background: Marine brown algae, Kjellmaniella crassifolia Miyabe (Gagome) is extensively harvested in Northern Japan and is known to help improve the immune system and prevent lifestyle diseases by its functional constituents, particularly the polysaccharide fucoidan. However, since most scientific findings come from animal studies, we examined its potential effectiveness in humans to raise immune functions, using small amounts of Gagome to avoid overconsumption of iodide. Methods: We set up a double-blind, placebo-controlled clinical trial (n=30 subjects for Gagome consumption; n=30 for placebo), in which 0.8 gram/day of Gagome containing 200 mg as dietary fiber (ca. 80 mg as fucoidan) was ingested for 8 weeks. The primary end-point was natural killer (NK) cell activity while other immune-related biomarkers, such as immunoglobulins (IgM and IgA) and cytokines (IL-12 and IFN-g) were secondary end-points.Results: No adverse effects were observed during the course of the clinical trial. We found that 8-week daily Gagome intake raised NK cell activities for the group with a relatively higher baseline number of NK cells (p=0.03). We also demonstrated that Gagome intake exerted a tendency to stimulate IgA secretion. These results indicate the possibility that Gagome intake may potentiate host defense systems in human as seen in animal studies.Conclusion: In this study, we used small amounts of Gagome (0.8 g daily) as an active test sample to avoid overconsumption of iodide, and found that this amount could enhance NK cell activities, particularly in the subclass with initially higher NK cell numbers. We also found an appreciable increment of IgA. With all of these facts, it seems that Gagome intake activates immune responses that contribute to the promotion of health through stimulation of the immune system.Keywords: clinical trial, dietary fiber, fucoidan, Gagome, natural killer cells
Collapse
|
64
|
Ishibashi Y, Kudo M, Yonezawa H, Shimoda H, Sakata K, Kobayashi S, Ogawa A, Terayama Y. Study of headache after the Great East Japan earthquake in Iwate coast area –comparison with migraineurs and non-migraineurs- part1. J Neurol Sci 2017. [DOI: 10.1016/j.jns.2017.08.3427] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
65
|
Kudo M, Ishibashi Y, Yonezawa H, Shimoda H, Sakata K, Kobayashi S, Ogawa A, Terayama Y. Study of headache after the Great East Japan earthquake in Iwate coast area. –Comparison with migraineurs and non-migraineurs - part 2. J Neurol Sci 2017. [DOI: 10.1016/j.jns.2017.08.3435] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
66
|
Finn R, Kudo M, Cheng AL, Wyrwicz L, Ngan R, Blanc JF, Baron A, Vogel A, Ikeda M, Piscaglia F, Han KH, Qin S, Minoshima Y, Funahashi Y, Ren M, Dairiki R, Sachdev P, Tamai T, Dutcus C, Evans T. Analysis of serum biomarkers (BM) in patients (pts) from a phase 3 study of lenvatinib (LEN) vs sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC). Ann Oncol 2017. [DOI: 10.1093/annonc/mdx440.022] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022] Open
|
67
|
Finn R, Chan S, Zhu A, Knox J, Cheng AL, Siegel A, Bautista O, Kudo M. KEYNOTE-240: Phase 3, randomized study of pembrolizumab (pembro) vs best supportive care (BSC) for second-line advanced hepatocellular carcinoma (HCC). Ann Oncol 2017. [DOI: 10.1093/annonc/mdx369.157] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
68
|
Kobayashi S, Ueshima K, Moriguchi M, Takayama T, Izumi N, Yoshiji H, Hino K, Oikawa T, Chiba T, Motomura K, Kato J, Yasuchika K, Ido A, Kinoshita J, Sato T, Ikeda M, Okusaka T, Kudo M, Tamura K, Furuse J. JET-HCC: A phase 3 randomized, double-blind, placebo-controlled study of tivantinib as a second-line therapy in patients with c-Met high hepatocellular carcinoma. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx369.003] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
69
|
Vogel A, Qin S, Kudo M, Hudgens S, Yamashita T, Yoon JH, Fartoux L, Simon K, López López C, Sung M, Dutcus C, Kraljevic S, Tamai T, Grunow N, Meier G, Breder V. Health-related quality of Life (HRQOL) and disease symptoms in patients with unresectable hepatocellular carcinoma (HCC) treated with lenvatinib (LEN) or sorafenib (SOR). Ann Oncol 2017. [DOI: 10.1093/annonc/mdx369.002] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
70
|
Nishimura M, Sugawara M, Kudo M, Nishihira J. A randomized, double-blind, placebo-controlled study to examine the effects of high-isoflavone soybeans “Yukipirika” in climacteric women. FUNCTIONAL FOODS IN HEALTH AND DISEASE 2017. [DOI: 10.31989/ffhd.v7i8.359] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Background: Soy isoflavones belong to a class of plant-based compounds known as phytoestrogens and effect menopausal symptoms and bone metabolism. We evaluated the effects of high-isoflavone soybeans (“Yukipirika”) in climacteric women.Methods: In this randomized, double-blind, placebo-controlled study, we randomly selected 64 female subjects (aged 46–60 years) to consume products made from high-isoflavone soybeans (active test), low-isoflavone soybeans (Placebo 2), or wheat (Placebo 1). The simplified menopausal index (SMI) test, visual analog scale (VAS) of skin and hair conditions, joints functions, and bowel movements, hematological analysis, and urinalysis were performed at weeks 0, 4, and 8 during the study period. Results: Intake of high-isoflavone soybeans did not change bone metabolism parameters. However, a subsection of the SMI score was improved in the active test food group compared to the Placebo 2 food group. Additionally, VAS of skin conditions, joints functions, and bowel movements improved in the active test group compared to the Placebo 1 or Placebo 2 groups. Conclusion: These results suggest that the ingestion of high-isoflavone soybeans can improve skin conditions, joints functions, and bowel movements, in addition to menopausal symptoms.Keywords: bone metabolism; clinical trial; isoflavone; soybeans; menopausal symptoms; Yukipirika
Collapse
|
71
|
Shimura T, Yamamoto M, Kano S, Kagase A, Kodama A, Koyama Y, Tsuchikane E, Suzuki T, Otsuka T, Kohsaka S, Tada N, Yamanaka F, Naganuma T, Araki M, Shirai S, Watanabe Y, Hayashida K, Yashima F, Inohara T, Kakefuda Y, Arai T, Yanagisawa R, Tanaka M, Kawakami T, Maekawa Y, Takashi K, Yoshitake A, Iida Y, Yamazaki M, Shimizu H, Yamada Y, Jinzaki M, Tsuruta H, Itabashi Y, Murata M, Kawakami M, Fukui S, Sano M, Fukuda K, Hosoba S, Sato H, Teramoto T, Kimura M, Sago M, Tsunaki T, Watarai S, Tsuzuki M, Irokawa K, Shimizu K, Kobayashi T, Okawa Y, Miyasaka M, Enta Y, Shishido K, Ochiai T, Yamabe T, Noguchi K, Saito S, Kawamoto H, Onishi H, Yabushita H, Mitomo S, Nakamura S, Yamawaki M, Akatsu Y, Honda Y, Takama T, Isotani A, Hayashi M, Kamioka N, Miura M, Morinaga T, Kawaguchi T, Yano M, Hanyu M, Arai Y, Tsubota H, Kudo M, Kuroda Y, Kataoka A, Hioki H, Nara Y, Kawashima H, Nagura F, Nakashima M, Sasaki K, Nishikawa J, Shimokawa T, Harada T, Kozuma K. Impact of the Clinical Frailty Scale on Outcomes After Transcatheter Aortic Valve Replacement. Circulation 2017; 135:2013-2024. [DOI: 10.1161/circulationaha.116.025630] [Citation(s) in RCA: 165] [Impact Index Per Article: 23.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/22/2016] [Accepted: 03/01/2017] [Indexed: 12/14/2022]
Abstract
Background:
The semiquantitative Clinical Frailty Scale (CFS) is a simple tool to assess patients’ frailty and has been shown to correlate with mortality in elderly patients even when evaluated by nongeriatricians. The aim of the current study was to determine the prognostic value of CFS in patients who underwent transcatheter aortic valve replacement.
Methods:
We utilized the OCEAN (Optimized Catheter Valvular Intervention) Japanese multicenter registry to review data of 1215 patients who underwent transcatheter aortic valve replacement. Patients were categorized into 5 groups based on the CFS stages: CFS 1-3, CFS 4, CFS 5, CFS 6, and CFS ≥7. We subsequently evaluated the relationship between CFS grading and other indicators of frailty, including body mass index, serum albumin, gait speed, and mean hand grip. We also assessed differences in baseline characteristics, procedural outcomes, and early and midterm mortality among the 5 groups.
Results:
Patient distribution into the 5 CFS groups was as follows: 38.0% (CFS 1-3), 32.9% (CFS4), 15.1% (CFS 5), 10.0% (CFS 6), and 4.0% (CFS ≥7). The CFS grade showed significant correlation with body mass index (Spearman’s ρ=−0.077,
P
=0.007), albumin (ρ=−0.22,
P
<0.001), gait speed (ρ=−0.28,
P
<0.001), and grip strength (ρ=−0.26,
P
<0.001). Cumulative 1-year mortality increased with increasing CFS stage (7.2%, 8.6%. 15.7%, 16.9%, 44.1%,
P
<0.001). In a Cox regression multivariate analysis, the CFS (per 1 category increase) was an independent predictive factor of increased late cumulative mortality risk (hazard ratio, 1.28; 95% confidence interval, 1.10–1.49;
P
<0.001).
Conclusions:
In addition to reflecting the degree of frailty, the CFS was a useful marker for predicting late mortality in an elderly transcatheter aortic valve replacement cohort.
Collapse
|
72
|
Howell J, Pinato DJ, Ramaswami R, Bettinger D, Arizumi T, Ferrari C, Yen C, Gibbin A, Burlone ME, Guaschino G, Sellers L, Black J, Pirisi M, Kudo M, Thimme R, Park JW, Sharma R. On-target sorafenib toxicity predicts improved survival in hepatocellular carcinoma: a multi-centre, prospective study. Aliment Pharmacol Ther 2017; 45:1146-1155. [PMID: 28252185 DOI: 10.1111/apt.13977] [Citation(s) in RCA: 38] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/14/2016] [Revised: 01/09/2017] [Accepted: 01/17/2017] [Indexed: 12/11/2022]
Abstract
BACKGROUND Hepatocellular carcinoma (HCC) is the sixth most common cancer worldwide and has high mortality despite treatment. While sorafenib has a survival benefit for patients with advanced HCC, clinical response is highly variable. AIM To determine whether development of sorafenib toxicity is a prognostic marker of survival in HCC. METHODS In this prospective multicentre cohort study, patients with advanced-stage HCC receiving sorafenib were recruited from five international specialist centres. Demographic and clinical data including development and grade of sorafenib toxicity during treatment, radiological response to sorafenib and survival time (months) were recorded prospectively. RESULTS A total of 634 patients with advanced-stage HCC receiving sorafenib were recruited to the study, with a median follow-up of 6692.3 person-months at risk. The majority of patients were male (81%) with Child-Pugh A stage liver disease (74%) and Barcelona Clinic Liver Cancer stage C HCC (64%). Median survival time was 8.1 months (IQR 3.8-18.6 months). 94% experienced at least one sorafenib-related toxicity: 34% diarrhoea, 16% hypertension and 37% hand-foot syndrome (HFS). Twenty-one per cent ceased sorafenib due to toxicity and 59% ceased treatment due to progressive disease or death. On multivariate analysis, sorafenib-related diarrhoea (HR 0.76, 95% CI 0.61-0.95, P = 0.017), hypertension (HR 0.531, 95% CI 0.37-0.76, P < 0.0001) and HFS (HR 0.65, 95% CI 0.51-0.81, P < 0.0001) were all significant independent predictors of overall survival after adjusting for age, severity of liver disease, tumour stage and sorafenib dose. CONCLUSION Development of sorafenib-related toxicity including diarrhoea, hypertension and hand-foot syndrome is associated with prolonged overall survival in patients with advanced-stage HCC on sorafenib.
Collapse
|
73
|
Ikeda M, Shimizu S, Sato T, Morimoto M, Kojima Y, Inaba Y, Hagihara A, Kudo M, Nakamori S, Kaneko S, Sugimoto R, Tahara T, Ohmura T, Yasui K, Sato K, Ishii H, Furuse J, Okusaka T. Reply to the Letter to the editor 'Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus Sorafenib for advanced hepatocellular carcinoma: randomized phase II trial' by Fornaro et al. Ann Oncol 2017; 28:903-904. [PMID: 28137738 DOI: 10.1093/annonc/mdx013] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2016] [Indexed: 11/12/2022] Open
|
74
|
Pinato DJ, Yen C, Bettinger D, Ramaswami R, Arizumi T, Ward C, Pirisi M, Burlone ME, Thimme R, Kudo M, Sharma R. The albumin-bilirubin grade improves hepatic reserve estimation post-sorafenib failure: implications for drug development. Aliment Pharmacol Ther 2017; 45:714-722. [PMID: 28116800 DOI: 10.1111/apt.13904] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/01/2016] [Revised: 10/20/2016] [Accepted: 11/24/2016] [Indexed: 12/18/2022]
Abstract
BACKGROUND Drug development in hepatocellular carcinoma (HCC) is limited by disease heterogeneity, with hepatic reserve being a major source of variation in survival outcomes. The albumin-bilirubin (ALBI) grade is a validated index of liver function in patients with HCC. AIM To test the accuracy of the ALBI grade in predicting post-sorafenib overall survival (PSOS) in patients who permanently discontinued treatment. METHODS From a prospectively maintained international database of 447 consecutive referrals, we derived 386 eligible patients treated with sorafenib within Barcelona Clinic Liver Cancer C stage (62%), 75% of whom were of Child class A at initiation. Clinical variables at sorafenib discontinuation were analysed for their impact on post-sorafenib overall survival using uni- and multivariable analyses. RESULTS Median post-sorafenib overall survival of the 386 eligible patients was 3.4 months and median sorafenib duration was 2.9 months, with commonest causes of cessation being disease progression (68%) and toxicity (24%). At discontinuation, 92 patients (24%) progressed to terminal stage, due to worsening Child class to C in 40 (10%). Median post-sorafenib overall survival in patients eligible for second-line therapies (n = 294) was 17.5, 7.5 and 1.9 months according respectively to ALBI grade 1, 2 and 3 (P < 0.001). CONCLUSIONS The ALBI grade at sorafenib discontinuation identifies a subset of patients with prolonged stability of hepatic reserve and superior survival. This may allow improved patient selection for second-line therapies in advanced HCC.
Collapse
|
75
|
Kudo M. Molecular Targeted Agents for Hepatocellular Carcinoma: Current Status and Future Perspectives. Liver Cancer 2017; 6:101-112. [PMID: 28275577 PMCID: PMC5340214 DOI: 10.1159/000452138] [Citation(s) in RCA: 26] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/04/2023] Open
|